ANIP Company Profile and Key Details

ANIP has shown mixed momentum, gaining 1.68% over the past week and -9.52% over the past quarter, though year-to-date performance is up 8.65%. Short-term trend indicators are mixed aligned (SMA20 -2.14%, SMA50 -4.22%, SMA200 -3.05%). The stock’s 14-day RSI is 43.66 (neutral), while the ATR of 2.63 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -22.46% below its high and over 42.61% above its low. Average 10-day trading volume of 433.65 thousand shares is slightly above the 3-month average of 383.86 thousand, indicating heightened recent market interest.

ANI Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$55.94. This means the shares are trading below this model’s fair value.

Wall Street analysts project EPS growth of 26.22% annually over the next five years. The latest quarter delivered EPS of $1.26. The next quarter is forecast at $1.99. Next year's EPS is expected at -$3.76. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 6 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $124.00 to $77.00. The high target offers 58.39% upside. The low target suggests -1.65% downside. The mean target is $103.30. This offers 31.95% upside. ANI Pharmaceuticals, Inc. earnings surprise history is a mixed track record. The quarter that ended November 07, 2025, missed forecasts by -27.59%. The prior quarter beat by 30.43%. Over the last six quarters, Apple has recorded several small beats. These include -112.73% in August 06, 2024.

ANI Pharmaceuticals, Inc. has 22.41 million shares outstanding. The public float is 19.00 million shares, elevated short interest at 20.04% of float. This equals 3.60 million shares. The short ratio is 9.68 days. Institutional investors hold 108.61% of the float. Insiders own 9.99%. MERIDIAN VENTURE PARTNERS II LP holds 1.82 million shares, Shanmugam Muthusamy has 431.92 thousand shares and Lalwani Nikhil has 411.22 thousand shares. Over the past six months, insider transactions show net selling. They sold 78.48 thousand shares across 25 transactions.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) closed at $77.85 USD, gaining $1.37 (1.79%) from the previous close of $76.48. The stock is currently mid-range between its 52-week high and low $56.71 and $99.50. With a market capitalization of about $1.74 billion, ANI Pharmaceuticals, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.43). Key stats such as the average daily volume over the past year has been around 382.84 thousand shares, volume is running light vs its 52-week average. Headquartered in Baudette, MN, ANI Pharmaceuticals, Inc. operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO Nikhil Lalwani, the company employs approximately 897 people and listed since May 05, 2000. ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANI Pharmaceuticals, Inc. trades at a P/E ratio of 20.56, slightly below the S&P 500 average, with a price-to-sales ratio of 1.97 and a price-to-book ratio of 2.88 suggesting the stock is closer to book value. The P/FCF stands at 13.57, also below market averages.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) shares are flat 8.65% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows ANI Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of 20.56. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $78.16, suggesting -0.17% downside. Our AI forecast model points to short-term strength (8.11% over two weeks), a medium-term fall (-12.16% over three months), and a longer-term gain (17.81% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that ANI Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 8.11%, with price expected at $84.64 by April 28, 2026, within a range of $83.15 to $86.06 3-Month Outlook: Projected fall of -12.16%, reaching $68.77 by July 13, 2026, with a range of $67.90 to $69.72. 1-Year Outlook: Projected gain of 17.81%, with price at $92.23 by April 14, 2027, within a range of $89.38 to $95.52.